Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001104659-25-119726
Filing Date
2025-12-09
Accepted
2025-12-09 17:26:01
Documents
10

Document Format Files

Seq Description Document Type Size
1 424B3 tm2533062d1_424b3.htm 424B3 1849830
2 GRAPHIC tm2533062d1_424b3img08.jpg GRAPHIC 4277
3 GRAPHIC tm2533062d1_424b3img07.jpg GRAPHIC 198851
4 GRAPHIC tm2533062d1_424b3img06.jpg GRAPHIC 78625
5 GRAPHIC tm2533062d1_424b3img05.jpg GRAPHIC 106553
6 GRAPHIC tm2533062d1_424b3img04.jpg GRAPHIC 87016
7 GRAPHIC tm2533062d1_424b3img03.jpg GRAPHIC 53099
8 GRAPHIC tm2533062d1_424b3img02.jpg GRAPHIC 162490
9 GRAPHIC tm2533062d1_424b3img09.jpg GRAPHIC 17624
10 GRAPHIC tm2533062d1_424b3img01.jpg GRAPHIC 7043
  Complete submission text file 0001104659-25-119726.txt   2811362
Mailing Address 804, 322 - 11 AVENUE SW CALGARY Alberta, Canada
Business Address 804, 322 - 11 AVENUE SW CALGARY Alberta, Canada 4036707377
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-290954 | Film No.: 251560054
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)